Prof. Kenneth Blum: Dopaminedysregulation in Neurology

Kenneth Blum 🧬🔬, a distinguished U.S. citizen 🇺🇸, Dopaminedysregulation in Neurology , boasts a robust academic journey culminating in a Ph.D. in Pharmacology from New York Medical College. With a wealth of expertise, he embarked on a fruitful postdoctoral stint at the Texas Biomedical Research Institute, delving into Psychopharmacology. Currently a Full Professor at Western University Health Sciences, his influence extends across diverse academic roles, including Adjunct Professor at Wright University and Research Professor Adjunct at the University of Vermont. Recognized as a trailblazer, he’s earned accolades like “Top 100 Scientist of the Year” and delivered keynote addresses globally, shaping the landscape of neuroscience and addiction research 🌐🧠.

Profile:

Scopus

🎓 Education:

Kenneth Blum 🎓, a luminary in the field, earned his B.S. in Pharmacy from Columbia University in 1961 🏛️. He delved deeper into the realm of academia, achieving an M.S. in Medical Science from The University of Medicine and Dentistry of New Jersey in 1965 🧪. Driven by passion, he secured a Ph.D. in Pharmacology from New York Medical College in 1968, guided by mentor Joseph Siefter 🧠. His journey continued with a pivotal postdoctoral stint at the Texas Biomedical Research Institute, focusing on Psychopharmacology in 1972 🌐. Later, a Fellowship in Genetics at the University of Colorado School of Pharmacy in 1978 added another dimension to his illustrious career 🧬.

🏥 Experience:

Kenneth Blum 🌐🧬, a versatile professional, has left an indelible mark in academia and business. Notably appointed at the University of Texas Health Science Center at San Antonio, he contributed to various committees, including the Promotions Committee and International Relations Committee 🎓. His leadership extends to diverse organizations, serving as Chairman for projects like the Hanging Bottle Research Project. In the business realm, Dr. Blum has held prominent roles, from Vice President of Research & Development at Zephra Corporation to Chairman & President of Pharmabyte Inc. His extensive advisory roles span across renowned entities like Weider International and PharmaVite Inc. 🏢🔬. As the Chief Scientific Officer for various healthcare centers, including Summit Estate Recovery Center and The Shores Recovery and Treatment Center, he continues to shape advancements in neurogenetics and addiction therapy. Currently, he holds the position of Executive Chairman at IngenEus, showcasing his enduring commitment to scientific innovation.

🏆Award & Honours:

Kenneth Blum 🏅, a trailblazer in research and academia, boasts a plethora of prestigious honors and awards spanning his illustrious career. Recognized as the “Top 100 Registry Scientist of the Year” in 2019, he has graced global stages as a keynote speaker, addressing influential conferences on neuroscience, addiction, and genetics 🗣️🌐. With a lifetime of achievements, Dr. Blum’s accolades include the “Who’s Who” Lifetime Achievement Award, the American Society of Addiction Medicine Millennium Lab Award, and the Julius Axelrod Distinguished Speaker Award. His impact extends beyond borders, with awards like the Titan Award and Marquis Who’s Who in America recognizing his expertise and contributions to addiction research 🌟🧬.

💡Research Scholarships:

Kenneth Blum 🧬🔍, a prolific researcher, has secured an impressive array of grants and contracts throughout his career, showcasing his commitment to advancing scientific knowledge. Notable achievements include his work on the “Psychogenetics of Drug Seeking Behavior” funded by NIDA, exploring genetic aspects of substance abuse 💊🧬. Dr. Blum’s contributions extend to areas like alcoholism, hormones, and menopause, with grants from entities such as the Seaver Foundation and the Southwest Research Institute 🍷🤰. His diverse research portfolio, spanning from the analysis of psychoactive drugs to finding genetic links to alcoholism, reflects a lifelong dedication to unraveling complex scientific puzzles 🔬🌐.

🔬Publications:

The Future is Now for Precision Genomic Addiction Medicine as a Front-line Modality for Inducing “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS)
- Authors: Gilley, E.D., Bowirrat, A., Gupta, A., Baron, D., Blum, K.
- Year: 2024
Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry
- Authors: Blum, K., Ashford, J.W., Kateb, B., Makale, M., Gold, M.S.
- Year: 2023
Genetic Correlates as a Predictor of Bariatric Surgery Outcomes after 1 Year
- Authors: Thanos, P.K., Hanna, C., Mihalkovic, A., Mastrandrea, L.D., Quattrin, T.
- Year: 2023
Preliminary Observations of Personalized Repetitive Magnetic Stimulation (PrTMS) Guided by EEG Spectra for Concussion
- Authors: Makale, M.T., Nybo, C., Keifer, J., Thanos, P.K., Murphy, K.T.
- Year: 2023
Personalized repetitive transcranial magnetic stimulation (prtms®) for post-traumatic stress disorder (ptsd) in military combat veterans
- Authors: Makale, M.T., Abbasi, S., Nybo, C., Dennen, C.A., Murphy, K.T.
- Year: 2023
The First Exploratory Personalized Medicine Approach to Improve Bariatric Surgery Outcomes Utilizing Psychosocial and Genetic Risk Assessments: Encouraging Clinical Research
- Authors: Thanos, P.K., Hanna, C., Mihalkovic, A., Mastrandrea, L.D., Quattrin, T.
- Year: 2023
Behavioral, Neurochemical and Developmental Effects of Chronic Oral Methylphenidate: A Review
- Authors: Senior, D., Ahmed, R., Arnavut, E., Badgaiyan, R.D., Thanos, P.K.
- Year: 2023
Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy—A Case-Series
- Authors: Bajaj, A., Han, D., Elman, I., Barh, D., Blum, K.
- Year: 2023
Futuristic Exploration of Addiction Neuroscience in the Genomic Era
- Authors: Blum, K., Elman, I., Bowirrat, A., Badgaiyan, R.D., Gold, M.S.
- Year: 2023
Neurogenetics and Epigenetics of Loneliness
- Authors: Bowirrat, A., Elman, I., Dennen, C.A., Murphy, K.T., Blum, K.
- Year: 2023

Kenneth Blum | Dopaminedysregulation in Neurology | Best Researcher Award